Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

Proof of concept with key oncology lead
24 May 2016

Redx Pharma Plc is pleased to announce that it has reached pre-clinical proof of concept stage with an oncology lead that has the potential to treat leukaemia and other blood cancers. The lead, a reversible BTK inhibitor, offers exciting potential to treat Chronic Lymphocytic Leukaemia (CLL) patients who have become resistant to the gold standard therapy, Imbruvica™ (ibrutinib). This is the seventh program to have advanced through Redx's innovative development pipeline to pre-clinical proof of concept and has been achieved in 20 months, ahead of standard industry averages.

BTK (Bruton's Tyrosine Kinase) is an important enzyme in the B-cell receptor signalling pathway and is implicated in blood cancers such as CLL. Ibrutinib, a key therapy for treating CLL, irreversibly inhibits BTK.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

Investor News

24 May 2016

Our unaudited interim results for the six months ended 31 March 2016 are available to download.

Investor Resources

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Applying our proprietary method to deliver multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details